Articles tagged with Alzheimer Disease
A study published in JAMA Neurology found insulin resistance associated with reduced global and regional brain glucose metabolism in late middle-age adults at risk for Alzheimer's disease. Lower glucose metabolism was linked to poorer performance in immediate memory tasks.
Ralph A. Nixon, a renowned neuroscientist, received the prestigious Zaven Khachaturian Award for his groundbreaking research on early brain changes associated with Alzheimer's disease. His work has helped scientists better understand the process of Alzheimer's development and progression.
Researchers from NYU Langone Medical Center presented new findings on Alzheimer's disease treatment at the 2015 Alzheimer's Association Conference. The studies focused on the development of monoclonal antibodies that can recognize oligomeric tau and Aβ, as well as pathological structures in Parkinson's disease human brains. Additionall...
A recent study reveals that ßCTF, a protein precursor to amyloid beta, initiates abnormalities leading to neuron loss in early Alzheimer's pathology. Drugging ßCTF levels may help slow or stop Alzheimer's progression.
Dr. Li Gan receives the Inge Grundke-Iqbal Award for her influential research on progranulin and amyloid accumulation in mouse models of Alzheimer's disease. Her work may protect against brain changes associated with the disease.
Researchers at Einstein College of Medicine presented multiple studies on risk factors and predictors of aMCI and dementia in older adults, including the impact of perceived stress, diet, and coping mechanisms. The findings suggest that early detection of cognitive decline is crucial for implementing effective preventive interventions.
Researchers found iron-laden microglia in specific brain regions of Alzheimer's patients, which could aid in earlier diagnosis and monitoring using advanced MRI techniques. The study suggests a new suspect for the disease, contradicting the long-held hypothesis that amyloid plaques are the primary cause.
The Alzheimer's Association recognized MetLife Foundation and GHR Foundation for their significant investments in Alzheimer's research and public information programs. These foundations have supported over $32 million in research initiatives, including prevention studies and innovative approaches to Alzheimer's care.
The Alzheimer's Association honored four leading scientists, including Alison Goate, Bengt Winblad, John Hodges, and Ian McKeith, for their groundbreaking research on Alzheimer's disease and dementia. The recognition aims to accelerate the global effort to eliminate Alzheimer's and advance research towards new treatments.
Scientists have developed a new class of monoclonal antibodies that target misfolding proteins in neurodegenerative diseases. The antibodies successfully reverse damage to brain tissue in animals, suggesting a potential therapeutic agent for Alzheimer's and Parkinson's diseases.
MetLife Foundation and GHR Foundation received the Jerome H. Stone Philanthropy Award for their significant investment in Alzheimer's research, totaling over $32 million. The awards recognize their impact on accelerating global efforts to eliminate Alzheimer's disease.
A recent study published in Molecular Aspects of Medicine has identified genetic markers that link an increased risk for developing both type 2 diabetes and Alzheimer's disease. The research, led by Dr. Giulio Maria Pasinetti, found specific genetic variations associated with higher susceptibility to both conditions.
Researchers identify a specific variation in brain waves of individuals with amnestic mild cognitive impairment (aMCI), which may indicate an early dysfunction related to Alzheimer's disease. The test uses electroencephalogram (EEG) technology, offering a more affordable and non-invasive alternative to other methods.
A study published by the American Academy of Neurology found that Alzheimer's disease causes different changes in the brain, or pathologies, in African-Americans compared to white Americans of European descent. African-Americans were more likely to have mixed pathologies and blood vessel disease in their brains.
A six-month trial conducted at the University of Kansas Medical Center found that older adults can improve their visual-spatial processing and attention levels by exercising for 75-225 minutes per week. The study's results suggest that intensity, rather than duration, is more important for benefits to brain function.
Researchers at Beth Israel Deaconess Medical Center developed an antibody that selectively detects and destroys a toxic protein causing widespread neurodegeneration after TBI, potentially preventing Alzheimer's disease and CTE. The treatment restores neurons' structural and functional abilities.
The Paul G. Allen Family Foundation has partnered with the Alzheimer's Association to award three grants totaling $500,000 to study the role of inflammation on characteristic plaques and tangles of devastating brain disease. Researchers aim to better understand the interactions between the immune system and Alzheimer's pathologies.
The Paul G. Allen Family Foundation has awarded $7 million to five research teams to investigate the fundamental causes of Alzheimer's disease. The projects will focus on uncovering the biological roots of the disease, including gene combinations, white matter damage, and pH levels.
Researchers found evidence of Alzheimer's-like pathologies in individuals with the APOE ε4 variant, including increased amyloid plaque and tau levels. This study provides a foundation for further research among patients at risk of Alzheimer's earlier than usual.
Researchers identified 10 communication patterns that support intimacy in couples affected by Alzheimer's disease, including 'news of the day,' 'sharing memories,' and 'delighting in the unexpected.' These patterns help caregivers and spouses maintain a caring relationship despite progressive decline.
Changes in key biomarkers of Alzheimer's disease during midlife may help identify those who will develop dementia years later. The study found that drops in amyloid beta 42 levels among cognitively normal participants are linked to the appearance of plaques in brain scans years later.
Researchers at Cedars-Sinai Medical Center tested two methods to preserve cognition in laboratory mice with Alzheimer's disease. Immune cells from bone marrow and a drug for multiple sclerosis were found to travel into the brain, resisting abnormalities associated with the condition. The study showed measurable benefits in mice.
A small study suggests that omega-3 fatty acids and antioxidant supplementation may clear amyloid-beta protein and reduce inflammation in neurological tissues of people with mild clinical impairment. Further clinical studies are needed to verify the findings.
Dr. Hartmuth Kolb was recognized for his pioneering research on neurofibrillary tangles (NFTs) and Alzheimer's disease (AD). His PET imaging tracers showed promise in evaluating NFT pathology, holding potential for disease diagnosis and monitoring.
A new study suggests a genetic link between high blood pressure and reduced Alzheimer's disease risk, with antihypertensive drugs possibly playing a protective role. Researchers analyzed genetic data from over 17,000 individuals and found a significant association between higher systolic blood pressure and lower Alzheimer's risk.
A new study found that errors on memory and thinking tests may signal Alzheimer's disease up to 13-18 years before the disease can be diagnosed. Those who scored lower overall had an increased risk of developing the disease, with higher scores associated with a lower risk.
Researchers discovered differences in brain inflammation between people with Down syndrome and Alzheimer's disease alone. The study found higher levels of inflammatory markers M2b in Down syndrome-related Alzheimer's, highlighting the need for tailored treatments.
A digital map of the ageing brain could aid diagnosis by comparing patients' scans with a detailed map of the healthy ageing brain. The atlas was able to pinpoint changes in brain structure that can be an underlying sign of early Alzheimer's disease.
A new drug discovery project, funded by a £3m Dementia Consortium, aims to target brain inflammation in Alzheimer's disease. The project will explore novel therapeutics to dampen the inflammatory response, which is believed to contribute to the disease's damage.
New brain-imaging research has found that the cortex is thicker on average in youth with Down Syndrome than in typically developing youth, despite lower overall cortical volume. This finding may provide new insights into early onset Alzheimer's disease susceptibility in individuals with Down Syndrome.
A study found that genetic variants predicting higher systolic blood pressure are associated with lower Alzheimer's risk and increased use of antihypertensive medication. The study suggests that either high blood pressure or antihypertensive therapy may play a protective role against Alzheimer's disease development.
A study published in NMR in Biomedicine found that brain cell density remains constant with age, contrary to previous assumptions that brain cell loss is associated with aging. The researchers used ultra-high-field MRI scans to make detailed images of the brain, revealing preserved cell density throughout the brain.
Researchers at Toyohashi University of Technology developed new agents to inhibit the production of amyloid-beta peptides, a main cause of Alzheimer's disease. The novel curcumin derivatives were proposed through molecular simulations and shown to bind strongly to amyloid precursor protein.
A study published in Neurology found that people with mild cognitive impairment or dementia due to Alzheimer's disease have abnormal levels of lysosomal proteins in their blood. These proteins, found in tiny nerve cell-derived blood particles called exosomes, may serve as biomarkers for early treatment and prevention.
A study found that stimulating cognitive activities improved cognitive performance but didn't affect brain markers of Alzheimer's. The findings suggest sustaining intellectual engagement helps preserve cognitive function in old age.
Scientists discover that amyloid precursor protein binds to FE65 and FE65L1 proteins to facilitate eye and muscle health. Mice lacking these proteins develop severe lens degeneration and muscle weakness, suggesting a potential therapeutic target for cataracts and Alzheimer's disease.
Research shows amyloid PET scans improve diagnosis and treatment outcomes for Alzheimer's patients, especially when used after an indeterminate FDG-PET scan. The study found that 17% of patients who received an amyloid scan experienced statistically significant improvements in cognition over a two-year follow-up.
A new study found that calcineurin inhibitor-based medications used by organ transplant recipients significantly lower the prevalence of dementia and Alzheimer's disease compared to national data. The research suggests that this treatment strategy may offer a protective effect against the development and progression of Alzheimer's.
Quantitative brain imaging techniques can detect early cognitive decline and prevent it by identifying key brain structures and lifestyle factors. Studies suggest that a 10% reduction in preventable lifestyle risks can prevent up to 3 million cases of Alzheimer's dementia worldwide.
The discovery of lymphatic vessels in the brain could have significant implications for understanding and treating neurological diseases such as autism, Alzheimer's, and multiple sclerosis. The findings, published in Nature, suggest that these vessels may play a major role in immune responses to neurodegenerative diseases.
A study published in Nature Neuroscience found a link between poor sleep and the accumulation of beta-amyloid protein, which is believed to trigger Alzheimer's disease. Researchers discovered that excessive sleep disturbances can lead to impaired long-term memory consolidation.
A groundbreaking Alzheimer's disease prevention trial is supported by $10 million in new funding, focusing on therapies targeting amyloid proteins. The trial will test two investigational anti-amyloid therapies to prevent or delay Alzheimer's symptoms in people at high genetic risk.
A study published in Scientific Reports reveals a direct link between amyloid-beta protein and memory loss in healthy brains, even before physical signs of degeneration appear. The research found that administering amyloid-beta to pond snails caused significant impaired memories, despite no visible brain damage.
A machine learning breakthrough enables fast and accurate measurement of metabolic profiles from biofluid samples, revolutionizing predictive medical screening. This technology accelerates the development of diagnostic tests for various diseases, potentially years before symptoms appear.
Researchers have identified molecules associated with Alzheimer's disease as crucial players in long-term depression, a process that weakens synapse connections. These findings suggest potential therapeutic targets for the treatment of Alzheimer's and other neurodegenerative diseases.
A new study published in Radiology found that degeneration of white matter in the brain may be an early marker of specific types of Alzheimer's disease. White matter damage was found to be more severe and widespread in patients with atypical AD forms, suggesting a potential biomarker for early diagnosis.
Researchers discovered that synapses facilitate the spread of Tau aggregates in Alzheimer's patients, which could counteract synaptic repair efforts. This new understanding has significant implications for developing therapeutic strategies against Alzheimer's disease.
A study found that repetitive head injuries can lead to the build-up of beta-amyloid in the brain, increasing the risk of dementia. Boxers were most affected, with four times more likelihood of developing beta-amyloid deposits and worse disease outcomes.
The study reveals amyloid beta-42 forms three flat structures with a 'salt bridge' that stabilizes its toxic shape. This discovery provides new insights into amyloid propagation in Alzheimer's disease and may impact the effectiveness of existing treatments.
Researchers have characterized early-stage changes in Alzheimer's-affected cells, revealing that even a small number of affected cells can cause widespread electrical activity disruption. This could lead to the development of new diagnostic methods, including electroencephalogram screening.
Researchers found that elevated blood sugar can rapidly increase amyloid beta levels in the brain, contributing to Alzheimer's disease. The study suggests a new connection between diabetes and Alzheimer's, providing a potential therapeutic target for treatment.
Researchers have discovered that green tea extract and exercise can slow the progression of Alzheimer's disease in mice, potentially reversing its effects. The study found that mice with Alzheimer's symptoms exhibited improved cognitive function and retention after receiving the compound EGCG and exercising.
A novel approach has been identified to block amyloid production in an Alzheimer's mouse model, promising a potential early therapeutic intervention. The study found that the most promising compound, P8, can be administered to individuals at high risk of developing the disease and may have few side effects.
Researchers found that simultaneous inhibition of multiple Class 1 HDACs led to improved memory restoration and synaptic growth in animal models of Alzheimer's disease. The study suggests a promising new therapeutic strategy for the treatment of this devastating neurodegenerative disorder.
Researchers at the University of Cambridge have identified a pathway linking proteins amyloid precursor protein and tau, which may be targeted for treatment. This discovery using human stem cells suggests that manipulating this pathway could halt disease progression.
A study published in Neurology found that individuals with higher occupational levels, such as professionals and engineers, lived up to three years longer than those with lower-level occupations. This suggests that mentally demanding jobs may help protect the brain from the effects of frontotemporal dementia.
A new study found that people with more challenging jobs may live up to three years longer than those with less skilled jobs after developing frontotemporal dementia. The cognitive reserve theory suggests that higher occupational levels build connections in the brain, creating a buffer against disease.
Researchers at MIT and Case Western Reserve University will collaborate to advance understanding of Down syndrome, aiming to improve quality of life for those born with it. The collaboration will focus on developing personalized human stem cell models and testing potential therapeutic treatments.
Researchers at Wayne State University are working on a new approach to diagnose Alzheimer's disease in its earliest stages. The goal is to develop affordable and portable tests that can be easily administered in senior centers or church basements, reducing barriers for African Americans who are disproportionately affected by the disease.
UCI MIND has been redesignated as an Alzheimer's Disease Research Center, allowing it to continue its impactful clinical and basic research programs. The center involves over 100 investigators studying the cellular, molecular, and clinical risk factors of Alzheimer's disease.